PYC Therapeutics (ASX:PYC) Total Long-Term Assets: A$5.39 Mil (As of Dec. 2025)


ASX:PYC PYC Therapeutics Ltd ASX:PYC
34 GF Score
Price A$1.56
! 2 Warning Signs
View Full Analysis

What is PYC Therapeutics Total Long-Term Assets?

PYC Therapeutics ASX:PYC +1.97% 34 Total Long-Term Assets is A$5.39 Mil as of Dec. 2025. GuruFocus rates ASX:PYC with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. PYC Therapeutics's Total Long-Term Assets for the quarter that ended in Dec. 2025 was A$5.39 Mil.

PYC Therapeutics Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for PYC Therapeutics's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PYC Therapeutics Total Long-Term Assets Chart

PYC Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.16 6.10 5.29 5.62 5.75

PYC Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.36 5.62 6.10 5.75 5.39
ASX:PYC
34GF Score
PYC Therapeutics Ltd ASX:PYC
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PYC Therapeutics Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of A$5.39 Mil mean?
PYC Therapeutics (ASX:PYC) has a Total Long-Term Assets of A$5.39 Mil as of Dec. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on PYC Therapeutics and its competitors.
Is PYC Therapeutics' Total Long-Term Assets too high?
PYC Therapeutics' current Total Long-Term Assets is A$5.39 Mil. Overall, PYC Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does PYC Therapeutics' Total Long-Term Assets compare to VRTX and REGN?
PYC Therapeutics' Total Long-Term Assets of A$5.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on PYC Therapeutics and its competitors. PYC Therapeutics's current Total Long-Term Assets is A$5.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PYC Therapeutics stock overvalued right now?
PYC Therapeutics (ASX:PYC) has a current Total Long-Term Assets of A$5.39 Mil. The current Total Long-Term Assets is A$5.39 Mil. PYC Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For PYC Therapeutics (ASX:PYC), the current Total Long-Term Assets is A$5.39 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PYC Therapeutics Business Description

Other Exchanges PYCXF:USA
Address 6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
34GF Score

Get the complete analysis for ASX:PYC

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.56
Price